RT Journal Article
SR Electronic
T1 Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.24.22282735
DO 10.1101/2022.11.24.22282735
A1 Assawakosri, Suvichada
A1 Kanokudom, Sitthichai
A1 Suntronwong, Nungruthai
A1 Chansaenroj, Jira
A1 Auphimai, Chompoonut
A1 Nilyanimit, Pornjarim
A1 Vichaiwattana, Preeyaporn
A1 Thongmee, Thanunrat
A1 Duangchinda, Thaneeya
A1 Chantima, Warangkana
A1 Pakchotanon, Pattarakul
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Klinfueng, Sirapa
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Mongkolsapaya, Juthathip
A1 Honsawek, Sittisak
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/11/27/2022.11.24.22282735.abstract
AB Objectives Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence of booster vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed to determine the serological immune response of COVID-19 booster after CoronaVac-priming.Methods A total of 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP), viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2, full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both binding and neutralizing antibodies against wild-type and Omicron was determined on day 90– 120 after booster.Results A waning of total RBD immunoglobulin (Ig) levels, anti-RBD IgG, and neutralizing antibodies against Omicron BA.1, BA.2, and BA.4/5 variants was observed 90–120 days after booster vaccination. Participants who received mRNA-1273 had the highest persistence of the immunogenicity response, followed by BNT162b2, AZD1222, and BBIBP-CorV. The responses between full and half doses of mRNA-1273 were comparable. The percentage reduction of binding antibody ranged from 50% to 75% among all booster vaccine.Conclusions The antibody response substantially waned after 90–120 days post-booster dose. The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of humoral immune responses against the Omicron variant compared to the inactivated BBIBP booster. Nevertheless, an additional fourth dose is recommended to maintain immune response against infection.HighlightsThe persistence of antibody responses is different among three vaccine platforms.Highly remained antibody levels were observed with the mRNA and viral vector booster.The half-dose mRNA-1273 can be used interchangeably with the full-dose mRNA-1273.The neutralizing activity against BA.5 was lower than wild type and BA.2 subvariant.A fourth dose is recommended for individuals who received an inactivated booster.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Registry of Clinical Trials (TCTR 20210910002)Funding StatementThis work was supported by the Health Systems Research Institute (HSRI), the National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University and King Chulalongkorn Memorial Hospital and was supported by the Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported by the National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB numbers 546/64 and 498/65).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript